{"disease":{"id":"pain-associated-with-fibromyalgia","name":"Pain associated with fibromyalgia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"neurontin","indication_name":"Pain associated with fibromyalgia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neurontin","generic_name":"Gabapentin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-activated calcium channels","drug_class":"Antiepileptic/Analgesic","quality_score":10,"revenue":null,"mechanism":"Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02234583","title":"An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2485,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT02187471","title":"Treatment of Pain Associated With Fibromyalgia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1301,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT02146430","title":"Treatment of Pain Associated With Fibromyalgia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1293,"lead_sponsor_name":"Daiichi Sankyo","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}